title: Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
abstract: Evidence of an emerging etiologic link between diabetes mellitus and several gastrointestinal malignancies is presented. Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined. Further supporting the prospect of etiologic linkage, the association of diabetes mellitus with colon cancer is consistently demonstrated to be independent of obesity. An increasing incidence of diabetes and obesity in the United States has led to a recent surge in incidence of hepatocellular cancer on the background of nonalcoholic fatty liver disease, and this disease is expected to commensurately grow in incidence. Widespread recognition of this emerging risk factor may lead to a change in screening practices. Although the mechanisms underlying the correlation are still under investigation, the role of insulin, the insulin-like growth factor-I, and related binding and signaling pathways as regulators of cell growth and cell proliferation are implicated in carcinogenesis and tumor growth. The potential role of metformin and other medications for diabetes mellitus in the chemoprevention, carcinogenesis, and treatment of gastrointestinal malignancies is also presented.
authors.affiliation: Department of Internal Medicine, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey, New Brunswick, NJ.
authors.forename: Dana J
authors.initials: DJ
authors.lastname: Herrigel
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Moss
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology*; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000209:etiology*; D048909:Diabetes Complications / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology*; D008687:Metformin / Q000627:therapeutic use; D065626:Non-alcoholic Fatty Liver Disease / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000209:etiology*; D000077205:Pioglitazone; D011230:Precancerous Conditions / Q000473:pathology; D017451:Receptors, Somatomedin / Q000378:metabolism* / Q000627:therapeutic use*; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D017451:Receptors, Somatomedin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin; D000077205:Pioglitazone